Researcher comment: Cabazitaxel a new third-line option in mCRPC | Ronald de Wit

Ronald de Wit tells us why the CARD trial results are likely to change the paradigm for the treatment of metastatic castration-resistant prostate cancer.

View more on Medicine Matters oncology: https://bit.ly/2AEa5vo

More on ESMO 2019: https://bit.ly/2m1WQAS

• #science_technology
• #medicine
• #oncology
• #cancer